{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-045083","form_type":"8-K","ticker":"COCP","cik":"0001412486","company_name":"Cocrystal Pharma, Inc.","filed_at":"2024-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.383285+00:00","generated_at":"2026-05-30T00:51:33.176904+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cocrystal Pharma Q3 net loss $4.9M; cash $13M; expects topline data from two studies soon","bullets":["Net loss Q3 2024 of $4.9M ($0.49 per share) vs $4.2M ($0.41) in Q3 2023 which included $1.6M legal settlement.","Cash and cash equivalents $13.0M as of Sep 30, 2024, down from $26.4M at Dec 31, 2023; working capital $12.3M.","R&D expenses $3.2M (down from $4.2M); G&A $1.8M (stable).","Expects topline results from Phase 2a influenza A challenge study (CC-42344) by year end 2024.","Topline results from Phase 1 norovirus/coronavirus study (CDI-988) expected late 2024/early 2025; cash sufficient for 12 months."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-045083","json":"https://secwatch.observer/filing/0001493152-24-045083.json","markdown":"https://secwatch.observer/filing/0001493152-24-045083.md","text":"https://secwatch.observer/filing/0001493152-24-045083.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1412486/000149315224045083/0001493152-24-045083-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1412486/000149315224045083/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:51:33.176904+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}